Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation

Phase 4

Active, not recruiting

• Conditions: Acute Kidney Injury; Liver Diseases
• Interventions: Drug: Normal saline; Drug: Dexmedetomidine

• Registration Number: NCT03522688
• Lead Sponsor: Asan Medical Center

Brief Summary

Acute kidney injury (AKI) following liver transplantation (LT) is associated with increased costs, morbidity, and mortality. Dexmedetomidine has known to have anti-inflammatory effect and has been shown to ameliorate IRI in several organs. However, the impact of Dexmedetomidine on AKI after LT is not determined yet. Therefore, this study aims to observe the renal protective effects of Dexmedetomidine after LT.

Detailed Description

Acute kidney injury (AKI) following liver transplantation (LT) has shown a wide range of incidence between 17% and 95% and is associated with increased costs, morbidity, and mortality. The etiology of AKI after LT is multifactorial. Among these factors, renal ischemia-reperfusion injury (IRI) caused by perioperative renal hypoperfusion is considered as one of the most important independent risk factors and recent reports have indicated that IRI is associated with an inflammatory cascade. Dexmedetomidine which is a highly selective agonist of α2-adrenergic receptors has known have anti-inflammatory effect and has been shown to ameliorate IRI in several organs. However, the impact of Dexmedetomidine on AKI after LT is not determined yet. Therefore, this study aims to observe the renal protective effects of Dexmedetomidine after LT.

Study Timeline

• Study Start: 2017-07-11
• Study First Submitted: 2018-05-01
• Study First Submitted QC: 2018-05-01
• Study First Posted: 2018-05-11
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-13
• Primary Completion: 2023-07-14
• Last Update Posted: 2023-07-17
• Study Completion: 2024-07-07

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 214

Inclusion Criteria

• living liver transplantation recipients

Read More

Exclusion Criteria

• preoperative renal dysfunction
• dual living donor liver transplantation
• severe cerebral artery disease
• severe cardio-pulmonary disease

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
control group	Normal saline	The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
treatment group	Dexmedetomidine	The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour

Primary Outcome Measures

Name	Time	Method
acute kidney injury	7 days	serum creatinine levels in postoperative 7 days

Secondary Outcome Measures

Name	Time	Method
hospital length of stay	up to 1 year	hospital length of stay (days)
delirium	postoperative day 7	The incidence of delirium
graft failure	1 year	recipient death or re-transplantation within 1 year
lactate level	3 days	serial lactate level during operation and postoperative 3 days
early allograft dysfunction	postoperative day 7	early allograft dysfunction
duration of mechanical ventilation	up to 1 year	duration of mechanical ventilation (hours)
intensive care unit length of stay	up to 1 year	intensive care unit length of stay (days)

Trial Locations

Locations (1)

Asan medical center; 🇰🇷 Seoul, Songpa-gu, Korea, Republic of